Chinese shares rallied at the close as technology equities led the market, despite concerns that the US would impose drug export restrictions from China.

The Shanghai Composite Index jumped 1.7%, or 63.09 points, to finish Thursday's trade at 3,875.31. The Shenzhen Component Index soared 3.4%, or 422.21 points, to 12,979.89.

Chinese drug equities dipped following reports that the Trump administration is looking at placing curbs on medicines from China, but the slump was offset by a surge in tech stocks, such as Cambricon Technologies (SHA:688256), which received approval from the Chinese securities regulator for a private share placement. The pricing details were not yet disclosed.

Zhongji Innolight (SHE:300308) and Eoptolink Technology (SHE:300502) both surged 14% and 13%, respectively.

In corporate news, Guangdong HEC Technology (SHA:600673) jumped 4.7% after plans to indirectly own a stake in Chindata China through a capital increase.

Huatai Securities' (SHA:601688, HKG:6886) Shanghai shares rose 3.5% after applying to list $3 billion medium-term bonds on the Hong Kong Stock Exchange.